Two Sigma Advisers LP Increases Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Two Sigma Advisers LP boosted its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 421.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 126,300 shares of the biotechnology company's stock after purchasing an additional 102,100 shares during the period. Two Sigma Advisers LP owned approximately 0.23% of Repligen worth $18,796,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of RGEN. Andra AP fonden bought a new stake in Repligen during the 2nd quarter valued at about $25,000. International Assets Investment Management LLC purchased a new position in shares of Repligen during the second quarter worth approximately $33,000. UMB Bank n.a. increased its position in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after acquiring an additional 130 shares during the period. Blue Trust Inc. raised its stake in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 127 shares in the last quarter. Finally, Quarry LP boosted its holdings in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 239 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Up 3.7 %

Shares of NASDAQ RGEN traded up $5.52 during mid-day trading on Monday, hitting $154.72. The stock had a trading volume of 484,038 shares, compared to its average volume of 660,290. The company has a 50 day moving average of $141.45 and a two-hundred day moving average of $141.66. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the business posted $0.23 earnings per share. As a group, equities research analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on RGEN shares. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They set a "peer perform" rating on the stock. Wells Fargo & Company assumed coverage on Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective for the company. Royal Bank of Canada reiterated an "outperform" rating and set a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Finally, StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a report on Friday, November 22nd. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.